Study record
NIA ITP rapamycin dose-response cohort (42 ppm arm)
Median lifespan, dose-response arm
Mus musculus (UM-HET3, genetically heterogeneous) — Multi-site NIA ITP dose-response cohort (same program as the 2009 14 ppm cohort) Tier 5 · Replicated animal lifespan verification: verified
1. Species / populationGenetically heterogeneous UM-HET3 mice, NIA ITP dose-response arm
2. Exposure, route, schedule42 ppm in chow, late-life initiation (NIA ITP protocol)
3. Comparator & durationControl chow, same-age cohort; followed to natural death
4. Endpoint & numeric resultMedian lifespan +26% (female) / +23% (male) at 42 ppm in chow; maximal lifespan also increased in both sexes
5. What this study did NOT establishNo human lifespan data; no dose-equivalence or safety data beyond this tested dietary concentration
Full record
| Intervention(s) | Rapamycin |
| Species | Mus musculus (UM-HET3, genetically heterogeneous) |
| Population | Multi-site NIA ITP dose-response cohort (same program as the 2009 14 ppm cohort) |
| Sample size | not specified in source animals verification: verified_2026-07-11 |
| Exposure | 42 ppm in chow — Late-life initiation, NIA ITP protocol (same initiation-age design as the 14 ppm cohort) verification: verified_2026-07-11 |
| Comparator | Control chow, same-age cohort |
| Duration | Followed to natural death (lifespan study) |
| Endpoint | Median lifespan, dose-response arm |
| Evidence tier | Tier 5 · Replicated animal lifespan |
| What was NOT established | Did not test human lifespan or human dose equivalence. Does not establish that higher doses continue to produce larger effects beyond 42 ppm (no higher-dose arm is reported in the sourcing brief), and does not establish safety of this dose in humans. |
Result values (as reported in sourcing brief)
| metric | median lifespan |
| female median lifespan change | +26% |
| male median lifespan change | +23% |
| dose | 42 ppm in chow (threefold the ~14 ppm used in the 2009 report) |
| maximal lifespan | Also increased in both sexes |
| sex difference note | Rapamycin increased lifespan more in females than in males at every dose tested, possibly reflecting sexual dimorphism in blood drug levels. |
| separation note | Separate study from Harrison 2009 (itp-2009-rapamycin). These are median-lifespan figures; the 2009 report's +14%/+9% are age at 90% mortality. |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11. PubMed/PMC/Lancet lookup; numbers cross-checked against abstract.Identifiers: PMID verified; DOI verified; PMC verified; trial registry ID not applicable. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| program | NIA Interventions Testing Program (ITP) |
| reported year | 2014 |
| pmid | 24341993 verified |
| doi | 10.1111/acel.12194 verified |
| journal | Aging Cell |
| pmc | PMC4032600 verified |
| authors | Miller RA, Harrison DE, Astle CM, et al. (NIA ITP) |
| year | 2014 |
| verified date | 2026-07-11 |
| verified method | PubMed/PMC/Lancet lookup; numbers cross-checked against abstract |
| verified note | Female median +16/+21/+26% at 4.7/14/42 ppm; at 42 ppm males +23% / females +26%; maximal lifespan up in both sexes — MATCHES abstract. |
| verification status | verified |
| reverified 20260808 | PMID re-confirmed against Europe PMC 2026-08-08; abstract states median lifespan +23% (male) to +26% (female) at threefold the 2009 dose. |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research